Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro
Alnylam's president tells Scrip the RNAi pioneer is offering outcomes-based contracts for its first ever product to payers in the European Union following Onpattro's approval there in August. He also says payers "must pay for innovation."
You may also be interested in...
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
The gene silencing specialist has signed a collaboration that CEO David Horn Solomon tells Scrip will help push Silence up among its peers in the RNAi space.
Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.